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PDH28
A DRUG COST MODEL FOR A CAPITATED 
PATIENT POPULATION WITHIN AN 
INTEGRATED HEALTH CARE SYSTEM
Patel RP, Petitta A, Andrews MJ
Henry Ford Health System, Bingham Farms, MI, USA
OBJECTIVE: To identify the factors predicting outpa-
tient drug costs and quantify their magnitude. METH-
ODS: Data were collected for the capitated patient popu-
lations enrolled at the sixty-one ambulatory internal
medicine, pediatric medicine, and family practice clinics
located within the 21 outpatient sites of the Henry Ford
Health System. Medicare risk patients were excluded
since these programs often have limited prescription ben-
efits. The data included drug costs, diagnoses, and demo-
graphic information. Many factors including age, gender,
HIV, diabetes, transplant, congestive heart failure, coro-
nary artery disease, and percent Medicaid were identified
as possible contributors towards these per member per
month (PMPM) drug costs. The data for each of these
factors were input into a multivariate linear regression
model as the independent variables, while prescription
PMPM costs were designated as the dependent variable.
The regression model was created using the SPSS soft-
ware program. RESULTS: Five factors found to be statis-
tically significant predictors of PMPM drug cost were the
percentage of patients: between ages 40 to 64 (P 
0.000); with diabetes (P  0.044); receiving HIV drug
treatment (P  0.034); who were female (P  0.025);
with a transplant diagnosis (P  0.000). The best-fit
model was $PMPM  [(41.88  % 40–64 years) 
(71.77  % of diabetic patients)  (775.6  % on HIV
drugs)  (2299  % of transplant patients)  (11.30 
% of female patients)]  0.0233 (adjusted r2  0.957).
Age of 65 or greater was not a significant predicator be-
cause Medicare enrollees were not included. CONCLU-
SION: Age of 40 to 64, diabetes, HIV, transplant, and fe-
male gender are the five factors strongly predictive of
drug costs in this capitated population. This model can
be used to risk adjust and predict the pharmaceutical
budgets of the various sites within an integrated health
system.
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FACTORS AFFECTING ASTHMATIC, DIABETIC, 
AND HYPERTENSIVE PATIENT SELF-REPORTED 
COMPLIANCE IN A PHARMACEUTICAL CARE 
DEMONSTRATION PROJECT
Chaikledkaew U, Kamath T, Johnson KA
Department of Pharmaceutical Economics and Policy, School 
of Pharmacy, University of Southern California, Los Angeles, 
CA, USA
Compliance with medication is defined as the extent to
which a patient’s medication taking behavior conforms
to medical or health professional’s advice. Noncompli-
ance leads to preventable adverse drug reactions, unnec-
essary hospitalizations and increase in subsequent health-
care costs. OBJECTIVES: To investigate factors that
influence patient compliance in a sample of elderly popu-
lation suffering from asthma, diabetes, and/or hyperten-
sion. METHODS: Data on 201 patients with asthma, di-
abetes, and/or hypertension were obtained from “Pharmacist
service questionnaire” surveys. The compliance was as-
sessed by using questions based on a validated Morisky
score. Patient compliance was modeled as a function of
four groups of variables (i.e., patient demographic char-
acteristics, health behavior, quality of life, and patient
satisfaction in phamacy service). Correlation between
these variables and patient compliance was estimated by
ordinary least square (OLS) and logistic regression meth-
ods. RESULTS: Based on the OLS analysis, the following
variables had a significant impact on patient compliance:
age (P  0.04), baseline compliance (P  0.001), and pa-
tient satisfaction with pharmacy service (P  0.03). Lo-
gistic regression analysis showed that age (odds ratio,
OR  1.05), high school graduation (OR  0.11), and
baseline compliance (OR  7.12) had a significant influ-
ence on patient compliance. CONCLUSION: The find-
ings suggest that older patients, patients with less than
high school education, and patients with high satisfaction
in pharmacy service are more likely to be compliant. Pa-
tients self-reporting good compliance with previous med-
ications are more likely to comply. These factors should
be taken into account to target interventions at noncom-
pliant patients.
PDH30
ROLE OF HRQL EVALUATION IN THE DRUG 
REGULATORY PROCESS: PRELIMINARY 
RESULTS FROM A EUROPEAN 
REGULATORY SURVEY
Acquadro C
Mapi Research Institute, Lyon, France, for the European 
Regulatory Issues on QoL Assessment (ERIQA) Group
BACKGROUND: The ERIQA Group was created, with
the following mission statement: “establishing principles
and practices for the integration of Health-related Qual-
ity of Life (HRQL) outcomes in the drug regulatory pro-
cess”. As part of its activities of year 1999, the ERIQA
Group surveyed European Regulatory Authorities (EMEA
and country-specific agencies). OBJECTIVES: To clarify
in more detail the role of HRQL in the European regula-
tory process of pharmaceutical products (registration, re-
imbursement and promotion), i.e., to better understand
how HRQL evaluation is considered by regulators; and
their potential needs with regards to HRQL issues.
METHODS: Three questionnaires were developed, one
for each regulatory area, and sent to 60 representatives of
regulatory agencies in the 15 European countries repre-
sented at the EMEA, among them the 30 CPMP mem-
bers. Questionnaires were divided in three informative
parts: generic/ID; specific, and perspectives for the future.
They covered the first 6 months of year 1999. PRELIMI-
